Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

694 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies.
Gajecki L, Lebedeva IV, Liao YR, Ambriz D, Carter LM, Kumpf M, Lovibond S, Hachey JS, Graham MS, Postow M, Lewis JS, Andrew DP, Baca M, Schöder H, Larson SM, Veach DR, Krebs S. Gajecki L, et al. Among authors: larson sm. J Nucl Med. 2025 Apr 1;66(4):605-611. doi: 10.2967/jnumed.124.268762. J Nucl Med. 2025. PMID: 39978817
Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications.
Kurtz K, Eibler L, Dacek MM, Carter LM, Veach DR, Lovibond S, Reynaud E, Qureshy S, McDevitt MR, Bourne C, Monette S, Punzalan B, Khayat S, Verma S, Kesner AL, Cheung NV, Schöder H, Gajecki L, Cheal SM, Larson SM, Scheinberg DA, Krebs S. Kurtz K, et al. Among authors: larson sm. Theranostics. 2023 Oct 8;13(15):5469-5482. doi: 10.7150/thno.87489. eCollection 2023. Theranostics. 2023. PMID: 37908719 Free PMC article.
Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies.
Kramer K, Pandit-Taskar N, Kushner BH, Zanzonico P, Humm JL, Tomlinson U, Donzelli M, Wolden SL, Haque S, Dunkel I, Souweidane MM, Greenfield JP, Tickoo S, Lewis JS, Lyashchenko SK, Carrasquillo JA, Chu B, Horan C, Larson SM, Cheung NV, Modak S. Kramer K, et al. Among authors: larson sm. J Hematol Oncol. 2022 Nov 12;15(1):165. doi: 10.1186/s13045-022-01383-4. J Hematol Oncol. 2022. PMID: 36371226 Free PMC article. Clinical Trial.
GPA33-pretargeted radioimmunotherapy with mono- and bivalent DOTA-based Lu-177-labeled radiohaptens in a mouse orthotopic liver xenograft model of metastatic human colorectal cancer.
Le Roux AB, Fung EK, Lee SG, Monette S, Xu H, Guo HF, Yang G, Ouerfelli O, Jungbluth A, Schöder H, Larson SM, Cheung NV, Cheal SM, Veach DR. Le Roux AB, et al. Among authors: larson sm. Theranostics. 2025 May 25;15(13):6274-6289. doi: 10.7150/thno.107209. eCollection 2025. Theranostics. 2025. PMID: 40521192 Free PMC article.
A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome.
Garcia-Manero G, Gaddh M, Platzbecker U, Lindsley RC, Larson SM, Chevassut T, Fenaux P, Komrokji R, Lyons R, Al-Kali A, Jiang Y, Bothos J, Townsley DM, Zeidan AM. Garcia-Manero G, et al. Among authors: larson sm. Ann Hematol. 2025 Mar;104(3):1577-1585. doi: 10.1007/s00277-024-06081-4. Epub 2025 Mar 28. Ann Hematol. 2025. PMID: 40153010 Free PMC article. Clinical Trial.
Phase 1 dose-escalation trial using convection-enhanced delivery (CED) of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma (DIPG).
Souweidane MM, Bander ED, Zanzonico P, Reiner AS, Manino N, Haque S, Carrasquillo JA, Lyashchenko SK, Thakur SB, Lewis JS, Donzelli M, Cheung NV, Larson SM, Kramer K, Pandit-Taskar N, Dunkel IJ. Souweidane MM, et al. Among authors: larson sm. Neuro Oncol. 2025 Feb 19:noaf039. doi: 10.1093/neuonc/noaf039. Online ahead of print. Neuro Oncol. 2025. PMID: 39969230
694 results